Intraoperative radioimmunodetection

Martin, Edward W.; Thurston, M.O.

doi:10.1002/(sici)1098-2388(199812)15:4<205::aid-ssu2>3.0.co;2-s

Cited by 12 publications

(14 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Over the last 20 years, intraoperative GP detection of tumor has been extensively studied in CRC patients by Martin and his colleagues at The Ohio State University [24-29,31-42]. For most of these studies, a mechanism of cancer-specific detection was designed in which monoclonal antibodies against TAG-72 tumor-associated glycoprotein that were coupled with iodine-125.…”

Section: Discussionmentioning

confidence: 99%

Combined use of preoperative 18F FDG-PET imaging and intraoperative gamma probe detection for accurate assessment of tumor recurrence in patients with colorectal cancer

et al. 2007

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Combined use of preoperative 18F FDG-PET imaging and intraoperative gamma probe detection for accurate assessment of tumor recurrence in patients with colorectal cancer

et al. 2007

View full text Add to dashboard Cite

show abstract

“…RIGS with second generation anti-TAG-72 antibody (murine CC49) was evaluated in 87 colorectal cancer patients [23,[25][26][27][28]. In 57 patients with primary colorectal cancers, CC49 localized 86% of the cancer.…”

Section: Rigs With Second Generation Anti-tag-72 Antibody (Cc49) Showmentioning

confidence: 99%

Radioimmunoguided surgery (RIGS), PET/CT image‐guided surgery, and fluorescence image‐guided surgery: Past, present, and future

Sun

Bloomston

Hinkle

et al. 2007

Journal of Surgical Oncology

Self Cite

View full text Add to dashboard Cite

(125)I-labeled anti-TAG-72 antibodies were applied in radioimmunoguided surgery (RIGS) to remove gross and occult tumors. It is challenging to handle (125)I-labeled materials. PET/CT image-guided surgery utilizes (18)FDG to monitor the biochemical activity of the tumor and to integrate pre- and postoperative imaging for complete tumor removal. PET/CT image-guided surgery only detects later stage disease. Fluorescence image-guided surgery using anti-TAG-72 antibodies may provide opportunities for intraoperative cancer detection of both gross and occult tumors.

show abstract

“…RIGS with anti-TAG-72 antibodies has been shown to detect 77% to 89% of primary colorectal cancers 13–15 and 78% to 97% of metastatic lesions in more than 300 patients 3, 5, 8, 11, 14, 16–23. Furthermore, RIGS detects both visible gross tumors and clinically occult disease within lymph nodes in more than 70% of the cases 11, 15, 16, 19, 22–28.…”

Section: Introductionmentioning

confidence: 99%

“…Furthermore, RIGS detects both visible gross tumors and clinically occult disease within lymph nodes in more than 70% of the cases 11, 15, 16, 19, 22–28. These cases would be undetectable by traditional surgical and pathological examination.…”

Section: Introductionmentioning

confidence: 99%

Near-Infrared Fluorescence Labeled Anti-TAG-72 Monoclonal Antibodies for Tumor Imaging in Colorectal Cancer Xenograft Mice

Zou

Povoski

et al. 2009

Mol. Pharmaceutics

Self Cite

View full text Add to dashboard Cite

Anti-TAG-72 monoclonal antibodies target the tumor-associated glycoprotein (TAG)-72 in various solid tumors. This study evaluated the use of anti-TAG-72 monoclonal antibodies, both murine CC49 and humanized CC49 (HuCC49ΔC H 2), for near-infrared fluorescent (NIR) tumor imaging in colorectal cancer xenograft models. The murine CC49 and HuCC49ΔC H 2 were conjugated with Cy7 monofunctional N-hydroxysuccinimide ester (Cy7-NHS). Both in vitro and in vivo anti-TAG-72 antibody binding studies were performed. The in vitro study utilized the human colon adenocarcinoma cell line LS174T that was incubated with Cy7, antibody-Cy7 conjugates, or excessive murine CC49 followed by the antibody-Cy7 conjugates and was imaged by fluorescence microscopy. The in vivo study utilized xenograft mice, bearing LS174T subcutaneous tumor implants, that received tail vein injections of Cy7, murine CC49-Cy7, HuCC49ΔC H 2-Cy7, or nonspecific IgG-Cy7 and were imaged by the Xenogen IVIS 100 system from 15 minutes to 288 hours. The biodistribution of the fluorescence labeled antibodies was determined by imaging the dissected tissues. The in vitro study revealed that the antibody-Cy7 conjugates bound to LS174T cells and were blocked by excessive murine CC49. The in vivo study demonstrated that murine CC49 achieved a tumor/blood ratio of 15 at 96 hours post-injection. In comparison, HuCC49ΔC H 2-Cy7 cleared much faster than murine CC49-Cy7 from the xenograft mice, and HuCC49ΔC H 2-Cy7 achieved a tumor/ blood ratio of 12 at 18 hours post-injection. In contrast, Cy7 and Cy7 labeled non-specific IgG resulted in no demonstrable tumor accumulation. When mice were injected with excessive unlabeled murine CC49 at 6 hours before the injection of murine CC49-Cy7 or HuCC49ΔC H 2-Cy7, both the intensity and retention time of the fluorescence from the tumor was reduced. In summary, the Cy7 labeled murine CC49 and HuCC49ΔC H 2 demonstrate tumor-targeting capabilities in living colorectal cancer xenograft mice and provide an alternative modality for tumor imaging.

show abstract

Intraoperative radioimmunodetection

Cited by 12 publications

References 12 publications

Combined use of preoperative 18F FDG-PET imaging and intraoperative gamma probe detection for accurate assessment of tumor recurrence in patients with colorectal cancer

Combined use of preoperative 18F FDG-PET imaging and intraoperative gamma probe detection for accurate assessment of tumor recurrence in patients with colorectal cancer

Radioimmunoguided surgery (RIGS), PET/CT image‐guided surgery, and fluorescence image‐guided surgery: Past, present, and future

Near-Infrared Fluorescence Labeled Anti-TAG-72 Monoclonal Antibodies for Tumor Imaging in Colorectal Cancer Xenograft Mice

Contact Info

Product

Resources

About